Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DULECT Trial: Durvalumab and Lenvatinib in Advanced and Recurrent Endometrial Carcinoma
NCT04444193Unknown
- Sponsor
- Shanghai First Maternal and Infant Health Hospital
- Start
- Aug 2020
- Primary completion
- May 2021
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
01
Overview
Open-label, single-arm trial of durvalumab and lenvatinib in endometrial carcinoma, sponsored by Shanghai First Maternal and Infant Health Hospital. Primary endpoints: Progression Free Survival at 3 years and Objective Response Rate at 3 years. Status: unknown.
02
Drugs
durvalumablenvatinib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT04444193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444193.